Oncology
Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.
This March 2020 article in Nature Reviews Drug Discovery outlines trends in the current landscape of clinical trials evaluating PD-1/PD-L1-targeted monoclonal antibodies, which are now the standard of care for 16 different types of cancer and tissue-agnostic indications. IQVIA and Cancer Research Institute collaborated on the analyses and report.
Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.